Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Interest Income

Income earned on cash, deposits, and investments held by the company.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $8.49M rose 29.7% year over year, ahead of the -2.7% change in trailing-twelve-month interest income. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at +77.3% a year.

Context

  • Interest income amounted to 38.7% of revenue in FY2025, down 10601.1 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +29.7% holds above the trailing-twelve-month pace of -2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.49M+7.9% QoQ
Last fiscal yearDec 2025
$27.4M-14.7% YoY
LTMJun 2026
$29.68M-2.7% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.7%——
1 year-14.7%——
3-year CAGR+77.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
27.4M USD
Year-over-year change
-14.7%
4-year CAGR
+204.7%

Interest Income vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's LTM Jun 2026 interest income of $29.68M is the highest of the 4 companies compared; the peer median is $10.45M.
  • Its year-over-year change of -2.7% is the 2nd highest of 4, against a peer median of -28.9%.
  • Interest income amounts to 41.7% of revenue for VRDN, versus a peer median of 39.5%.
VRDN Competitors Peer median
Interest Income for VRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRDNViridian Therapeutics, Inc.LTM Jun 2026$29.68M -2.7%+77.3%41.7%
OCULOcular Therapeutix, Inc.LTM Mar 2026$20.58M +1.9%+184.4%39.5%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$10.45M -28.9%+76.7%137.3%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3 -100.0%—0.0%
Peer median (excluding VRDN) $10.45M-28.9%+130.5%39.5%

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.96M1.77M314K302K70.85M
Cost of Revenue00000
Gross Profit2.96M1.77M314K302K70.85M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development56.89M100.89M159.77M238.25M338.93M
Selling, General & Admin25.81M35.18M95M61.08M95.32M
Operating Expenses82.69M136.08M254.76M299.34M434.24M
Depreciation & Amortization120K255K522K540K460K
EBITDA(79.29M)(129.13M)(235.37M)(266.36M)(337.19M)
EBITDA Margin-2676.0%-7287.4%-74957.0%-88199.7%-475.9%
Operating Income(79.73M)(134.3M)(254.45M)(299.04M)(363.4M)
Operating Margin-2690.8%-7579.2%-81035.0%-99018.2%-512.9%
Interest Income318K4.92M18.56M32.13M27.4M
Interest Expense3K486K1.85M3.05M4.95M
Other Income / Expenses315K4.43M16.72M29.09M20.79M
Income Before Tax(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Pre-Tax Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
Income Tax Expense00000
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Net Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
EPS (Basic)(6.66)(3.91)(5.31)(3.98)(3.32)
EPS (Diluted)(6.66)(3.91)(5.31)(3.98)(3.32)
Weighted Avg Shares11.92M32.09M44.76M67.89M84.8M
Weighted Avg Shares (Diluted)11.92M32.09M44.76M67.89M84.8M

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.